BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16372186)

  • 1. [Therapy strategies for advanced renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Adam C; Stief CG
    Urologe A; 2006 Jan; 45(1):99-110, quiz 111-2. PubMed ID: 16372186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Palliative and supportive therapy in cases of renal cell carcinoma].
    Kurosch M; Buse S; Bedke J; Wagener N; Haferkamp A; Hohenfellner M
    Urologe A; 2007 Jan; 46(1):40-4. PubMed ID: 17186190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma.
    Mulders PF
    World J Urol; 2008 Apr; 26(2):113. PubMed ID: 18389254
    [No Abstract]   [Full Text] [Related]  

  • 5. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic opportunities in metastatic renal cell carcinoma].
    Buess M
    Praxis (Bern 1994); 2009 Apr; 98(9):481-6. PubMed ID: 19404907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors in kidney cancer].
    Patard JJ
    Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
    [No Abstract]   [Full Text] [Related]  

  • 9. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
    Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of targeted therapy in combination with surgery in renal cell carcinoma.
    Bex A; Powles T; Karam JA
    Int J Urol; 2016 Jan; 23(1):5-12. PubMed ID: 26238981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches in metastatic renal cell carcinoma.
    Staehler M; Rohrmann K; Bachmann A; Zaak D; Stief CG; Siebels M
    BJU Int; 2005 Jun; 95(8):1153-61. PubMed ID: 15877725
    [No Abstract]   [Full Text] [Related]  

  • 12. The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.
    Doehn C; Grünwald V; Steiner T; Follmann M; Rexer H; Krege S
    Dtsch Arztebl Int; 2016 Sep; 113(35-36):590-6. PubMed ID: 27658472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of therapy for advanced renal cell carcinoma.
    Basso M; Cassano A; Barone C
    Urol Oncol; 2010; 28(2):121-33. PubMed ID: 19576800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Pantuck AJ; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal cell carcinoma: current status and future prospects.
    Drucker BJ
    Cancer Treat Rev; 2005 Nov; 31(7):536-45. PubMed ID: 16236454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.